市場調査レポート

商品コード

1554287

3Dプリンティング医薬品の市場規模、シェア、成長分析：剤形別、技術タイプ別、用途別、地域別- 産業予測、2024年～2031年

3D Printed Drugs Market Size, Share, Growth Analysis, By Dosage Form (Tablet, Capsule), By Technology Type (Inkjet Printing, Direct Write), By Application (Orthopedic, Neurology), By Region - Industry Forecast 2024-2031

出版日: 2024年09月01日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 795,318円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 930,372円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,065,426円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=150.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

3Dプリンティング医薬品の世界市場規模は、2022年に8,490万米ドルと評価され、予測期間（2024-2031年）のCAGRは16%で、2023年の9,850万米ドルから2031年には3億2,291万米ドルに成長すると予測されています。

3Dプリンティング医薬品の世界市場は、医薬品分野で急成長を遂げています。この技術は、カスタマイズされた薬剤製剤を製造し、薬剤の有効性を高め、副作用を最小限に抑え、個別化された投与を可能にするためにますます活用されています。医薬品製造における3Dプリンティングは、基材上に正確な用量の薬剤を層ごとに作成するものであり、治療に対するより個別化されたアプローチを提供します。北米が市場をリードし、欧州、アジア太平洋がこれに続く。この成長を促進する主な要因には、個別化医療に対する需要の高まり、3Dプリンティングによって得られる精度と副作用の軽減、継続的な技術の進歩などがあります。3Dプリンティング医薬品市場の主な目的は、患者の転帰を向上させ、ヘルスケアコストを削減する革新的な医薬品製造方法を導入することです。3Dプリンティング技術は、より柔軟な薬剤設計を可能にし、無駄を最小限に抑え、オンデマンド生産を容易にします。このような利点がある一方で、3Dプリンティング技術に関連する高コストや医薬品承認のための規制上のハードルといった課題に直面しています。その他の課題としては、安全性と有効性を確保するためのさらなる調査の必要性、印刷プロセスの標準化、潜在的な知的財産権の衝突などがあります。しかし、新規製剤の開発、新地域への進出、ドラッグデリバリーや個別化医療の変革の可能性など、市場には大きなチャンスもあります。また、この技術は製薬企業に新たな収益源をもたらす可能性もあります。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Aprecia Pharmaceuticals, LLC（US）
FabRx Ltd（UK）
Cycle Pharmaceuticals（UK）
GlaxoSmithKline plc（UK）
AstraZeneca（UK/Sweden）
Tvasta（India）
Merck KGaA（Germany）
Terumo Corporation（Japan）
Extend Biosciences（US）
BioDuro（US）
Affinity Therapeutics（US）
Osmotica Pharmaceuticals（US）
Pfizer（US）
Sanofi（France）
3D Systems（US）
BASF（Germany）
Teva Pharmaceuticals（Israel）
Novartis（Switzerland）
Roche（Switzerland）
Catalent（US）
Johnson & Johnson（US）
Vertex Pharmaceuticals（US）
Boehringer Ingelheim（Germany）
Siemens Healthineers（Germany）
Sandoz International（Germany）
BioBots（US）
Apium Additive Technologies（Germany）
Boston Micro Fabrication（US）

Product Code: SQMIG35I2140

Global 3D Printed Drugs Market size was valued at USD 84.9 Million in 2022 and is poised to grow from USD 98.50 Million in 2023 to USD 322.91 Million by 2031, at a CAGR of 16% during the forecast period (2024-2031).

The global market for 3D-printed drugs is experiencing rapid growth within the pharmaceutical sector. This technology is increasingly utilized to produce customized drug formulations, enhancing drug effectiveness, minimizing side effects, and enabling personalized dosing. 3D printing in drug manufacturing involves the layer-by-layer creation of precise doses of medication on a substrate, offering a more tailored approach to treatment. North America leads the market, followed by Europe and Asia Pacific. Key factors driving this growth include the rising demand for personalized medicine, the precision and reduced side effects afforded by 3D printing, and ongoing technological advancements. The main objectives of the 3D-printed drugs market are to introduce innovative drug manufacturing methods that enhance patient outcomes and lower healthcare costs. 3D printing technology enables more flexible drug design, minimizes waste, and facilitates on-demand production. Despite these advantages, the market faces challenges such as high costs associated with 3D printing technology and regulatory hurdles for drug approval. Additional challenges include the need for further research to ensure safety and efficacy, standardization of printing processes, and potential intellectual property conflicts. However, the market also holds significant opportunities, such as the development of novel drug formulations, expansion into new regions, and the potential transformation of drug delivery and personalized medicine. This technology could also open new revenue streams for pharmaceutical companies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global 3D Printed Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global 3D Printed Drugs Market Segmental Analysis

The global 3D printed drugs market is segmented based on dosage form, technology, application, and region. Based on technology, the market is segmented into Inkjet Printing, Direct Write, Zip Dose, Thermal Inkjet Printing, Fused Deposition Modelling, Powder Bed Printing, Stereolithography (SLA) and Semi Solid Extrusion (SSE). Based on application, the market is segmented into orthopedics, neurology, dental, and others. Based on dosage form, the market is segmented into Tablet, Capsule, Multidrug Implant, Nanoparticles, Solutions and Other Products. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and MEA.

Drivers of the Global 3D Printed Drugs Market

The global market for 3D-printed drugs is being significantly driven by the growing demand for personalized medicines. These medicines, tailored to individual patients based on their genetic, environmental, and lifestyle factors, offer numerous benefits over conventional drugs, such as enhanced efficacy, fewer side effects, and better patient adherence. 3D printing technology plays a crucial role in this sector by enabling the production of customized drug formulations with precise dosing and specific drug release profiles. This technology allows for the creation of drug products with unique geometries and formulations that traditional manufacturing methods cannot achieve. The rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular conditions, further fuels the demand for personalized medicines. Such conditions often require ongoing treatment, and personalized drugs can significantly improve patient outcomes and overall quality of life. By facilitating targeted drug delivery, 3D printing can reduce the necessary dosage, thereby minimizing side effects and enhancing patient compliance. As both the demand for personalized medications and advancements in 3D printing technology continue to grow, the global 3D-printed drugs market is anticipated to expand rapidly in the coming years.

Restraints in the Global 3D Printed Drugs Market

he substantial initial investment needed for 3D printing equipment, software, and materials poses a significant challenge for small and medium-sized pharmaceutical companies looking to adopt this technology. The high costs associated with these resources can make 3D printing less accessible for many companies, limiting their ability to participate in the market. Additionally, the cost per unit for 3D-printed drugs tends to be higher compared to traditional drugs, primarily due to the expensive materials and the intricate production process involved. This higher cost can make 3D-printed medications less affordable for patients, potentially diminishing their market demand. Moreover, the regulatory landscape for 3D-printed drugs is still evolving, with approval processes often being both lengthy and costly. This regulatory uncertainty can further drive up the costs associated with 3D-printed drugs and restrict their availability to patients. As a result, the combination of high production costs and regulatory challenges can limit the widespread adoption and accessibility of 3D-printed pharmaceuticals.

Market Trends of the Global 3D Printed Drugs Market

The increasing collaboration between pharmaceutical companies and 3D printing firms is significantly advancing the global 3D Printed Drugs market. This partnership is accelerating innovation and expediting the development and market entry of new drugs and drug delivery systems. By working together, pharmaceutical companies and 3D printing specialists are leveraging the technology's capabilities to create complex and customized drug formulations with precise dosing and tailored characteristics. These collaborations are not only streamlining the development process but are also contributing to faster market introductions of novel drug products and delivery mechanisms. As this trend continues, it is expected to drive further growth in the 3D printed drugs sector, enhancing the industry's ability to meet evolving medical needs and patient preferences in the coming years.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors of The Market
Value Chain Analysis
Top Investment Pockets
Market Attractive Index
Ecosystem Mapping
Pricing analysis
Value chain analysis
Patent analysis
Regulatory analysis
Porter's five forces analysis

Global 3D Printed Drugs Market by Dosage Form

Market Overview
Tablet
Capsule
Multidrug Implant
Nanoparticles
Solutions
Other Products

Global 3D Printed Drugs Market by Technology Type

Market Overview
Inkjet Printing
Direct Write
Zip Dose
Thermal Inkjet Printing
Fused Deposition Modelling
Powder Bed Printing
Stereolithography (SLA)
Semi Solid Extrusion (SSE)

Global 3D Printed Drugs Market by Application

Market Overview
Orthopedic
Neurology
Dental
Others

Global 3D Printed Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Aprecia Pharmaceuticals, LLC (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
FabRx Ltd (UK)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Cycle Pharmaceuticals (UK)
- Company overview
- Business segment overview
- Financial updates
- Key developments
GlaxoSmithKline plc (UK)
- Company overview
- Business segment overview
- Financial updates
- Key developments
AstraZeneca (UK/Sweden)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Tvasta (India)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Merck KGaA (Germany)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Terumo Corporation (Japan)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Extend Biosciences (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
BioDuro (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Affinity Therapeutics (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Osmotica Pharmaceuticals (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Pfizer (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Sanofi (France)
- Company overview
- Business segment overview
- Financial updates
- Key developments
3D Systems (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
BASF (Germany)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Teva Pharmaceuticals (Israel)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Novartis (Switzerland)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Roche (Switzerland)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Catalent (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Johnson & Johnson (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Vertex Pharmaceuticals (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Boehringer Ingelheim (Germany)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Siemens Healthineers (Germany)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Sandoz International (Germany)
- Company overview
- Business segment overview
- Financial updates
- Key developments
BioBots (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Apium Additive Technologies (Germany)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Boston Micro Fabrication (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments

3Dプリンティング医薬品の市場規模、シェア、成長分析：剤形別、技術タイプ別、用途別、地域別- 産業予測、2024年～2031年

3D Printed Drugs Market Size, Share, Growth Analysis, By Dosage Form (Tablet, Capsule), By Technology Type (Inkjet Printing, Direct Write), By Application (Orthopedic, Neurology), By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

3Dプリンティング医薬品市場：剤形別

3Dプリンティング医薬品市場：技術タイプ別

3Dプリンティング医薬品市場：用途別

3Dプリンティング医薬品市場規模：地域別